ASLAN Pharmaceuticals: ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference

SAN MATEO, Calif. and SINGAPORE, April 24, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that an abstract on eblasakimab in Chronic Obstructive Pulmonary Disease has been accepted for a late breaking poster presentation at the American Thoracic Society International Conference 2024. The conference is taking place in San Diego, California, from May 17 to 22, 2024.American Thoracic Society International Conference poster detailsPoster title: Eblasakimab Significantly Alleviates IL-4 and IL-13 Induced Bronchial Airway Constriction in COPD-Derived Lung Slices (Poster ID 13753)Presentation date and time: Monday, May 20, 2024, 9:15 am PDTPresenter: Dr Ferda Cevikbas, Head, Translational Science, ASLAN PharmaceuticalsThe posters will be available to view online in the Publications section of ASLAN's website following presentation.About ...Full story available on Benzinga.com